系统用二甲双胍治疗黄褐斑有效吗？

Does Systemic Metformin Have a Role in Treating Melasma?

机构信息

Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt.

Department of Internal Medicine, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt.

出版信息

Dermatol Surg. 2024 Apr 1;50(4):366-371. doi: 10.1097/DSS.0000000000004092. Epub 2024 Feb 28.

DOI:10.1097/DSS.0000000000004092

PMID:38416809

Abstract

BACKGROUND

Melasma is a common pigmentary condition that affects the patients' quality of life and all the prescribed treatment options till now are not satisfactory, especially in dark-skinned patients.

OBJECTIVE

To evaluate the efficacy and safety of systemic metformin (1,000 mg and 500 mg) combined with trichloroacetic acid (TCA) peeling versus TCA alone in the treatment of melasma.

PATIENTS AND METHODS

The study included 60 melasma patients divided into 3 groups: Group A received systemic metformin (1000 mg/d), Group B received systemic metformin (500 mg/d) and Group C received placebo. The 3 treatment groups were treated by TCA 25% over the whole face bimonthly for a total of 6 sessions. Melasma area and severity index (MASI), and Melasma impact Quality of life Scale (MELASQOL) were used to assess the outcome.

RESULTS

There was a statistically significant decrease in the MASI, and the MELASQOL in the 3 studied groups after treatment with significantly better improvement in Group (A) than Group (C) ( p = .045).

CONCLUSION

Systemic metformin is a safe and promising therapeutic option for treating melasma.

摘要

背景

黄褐斑是一种常见的色素沉着性疾病，影响患者的生活质量，迄今为止所有的规定治疗方案都不尽如人意，尤其是在深色皮肤患者中。

目的

评估系统二甲双胍（1000mg 和 500mg）联合三氯乙酸（TCA）剥落与单独 TCA 治疗黄褐斑的疗效和安全性。

患者和方法

该研究纳入了 60 名黄褐斑患者，分为 3 组：A 组接受系统二甲双胍（1000mg/d），B 组接受系统二甲双胍（500mg/d），C 组接受安慰剂。3 个治疗组通过 TCA 25%在整个面部每两个月进行一次治疗，共 6 次。采用黄褐斑面积和严重程度指数（MASI）和黄褐斑影响生活质量量表（MELASQOL）评估疗效。